Reuters exclusively reports WHO-led COVID drug scheme doubles down on antibodies, steroids and shuns remdesivir


Reuters exclusively reported that a World Health Organization-led (WHO) scheme to supply COVID-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but shunning Gilead’s remdesivir therapy. According to an Oct. 30 WHO draft document seen by Reuters, priorities are to secure monoclonal antibodies in a tight market and to boost distribution of cheap steroid dexamethasone. The paper, which for the first time outlines how the scheme would spend donors’ money, does not cite remdesivir among priority drugs – a significant omission as the antiviral is the only other medication alongside dexamethasone approved across the world for treating COVID-19.

Article Tags

Topics of Interest: Health

Type: Reuters Best

Regions: Europe

Countries: Germany

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Source link

What do you think?

Written by Chekmagazine


Leave a Reply

Your email address will not be published. Required fields are marked *



The Fannie and Freddie Conundrum

China’s Riskier Companies Pay Up to Raise Bond Financing